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A B S T R A C T
Purpose: We developed a prognostic scoring system to evaluate the prognosis of myelodysplastic
syndrome (MDS) patients surviving more than 100 days allogeneic hematopoietic cell transplantation
after (allo-HCT).
Patients and methods: We performed a landmark analysis on a derivation cohort of 393 cases to identify
prognostic factors for 3-year overall survival. Potential predictor variables included demographic and
clinical data, transplantation modalities and early post-transplant complications. The scoring system was
tested against a validation cohort which included 391 patients.
Results: Complications occurring before day 100 such as relapse [HR = 6.7; 95%CI, 4.5-10.0] (4 points), lack
of platelet recovery [HR, 3.6; 95%CI, 2.2-5.8] (2 points), grade-II acute GVHD [HR = 1.7; 95%CI, 1.2-2.5] (1
point) and grade-III/IV [HR = 2.6; 95%CI, 1.8 -3.8] (2 points) were the only independent predictors of 3-
year OS.
The 3-year OS associated with low (0), intermediate (1-3) and high (4) risk scores was respectively 70%,
46% and 6%. The model performed consistently in both cohorts, with good calibration.
Conclusion: This post-transplant scoring system is a powerful predictor of outcome after allo-HCT for
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scoring system for other hematologic malignancies.
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Allogeneic hematopoietic cell transplantation (allo-HCT) is a
therapeutic option for high-risk hematological disorders including
myelodysplastic syndrome (MDS) [1,2]. Nevertheless, this ap-
proach is still associated with potentially life-threatening com-
plications such as conditioning-related toxicity, graft-versus-host
disease (GVHD), poor graft function and relapse [3,4].
A key issue is managing patients with post-transplant
complications. In addition, there is a need for a clinical tool that
provides more cost-effective use of medical resources by stream-
lining the selection process of those patients who will truly benefit
from curative care, including intensive care.
While most published scoring systems have focused on
prognostic variables determined before allo-HCT [5–7], there are
limited data regarding post-transplant prognostic evaluation,
particularly within a specific disease type.
We hypothesized that a more complex model including early
post-transplant events might be a more accurate predictor of.
survival for those patients who have already been transplanted.
Therefore, we developed a prognostic scoring system based on
homogenous cohorts of transplanted MDS patients which takes
into account disease characteristics and transplantation modalities
as well as early post-transplant complications.
PATIENTS AND METHODS
This multicenter study was approved by the board of the
Francophone Society of Bone Marrow Transplantation and Cellular
Therapy (SFGM-TC), and was conducted in accordance with the
Declaration of Helsinki. Written consent to use medically relevant
data for research purposes was obtained from each patient and
donor before transplant. To ensure confidentiality, each case was
anonymized by assignment of a random identification number.
Data Source
The SFGM-TC database (ProMISe) was used to retrieve data
from patients who underwent allo-HCT for MDS. In addition to an
independent monitoring double-check, the quality of the data was
controlled via a computerized search for discrepancy errors and
vigorous on-site data verification of each file. HLA matching was
cross-checked with the data of the French Bone Marrow Donor
Registry as previously described [8,9].
Patient Selection
Two distinct cohorts of patients were used for this study, a
derivation cohort and a validation cohort, with matching inclusion
and exclusion criteria.
The derivation dataset came from the derivation cohort of
patients (n = 461) treated for MDS with allo-HCT from January 1999
to December 2009.
Similarly, the validation dataset included all data from patients
(n = 451) treated for MDS with allo-HCT from January 2010 to
December 2013.
For inter-cohort homogeneity purposes, we only included
patients who received a first allo-HCT. Stem cell sources were
either bone marrow or peripheral blood stem cells (PBSC) from a
sibling or HLA-matched (so-called 10/10) unrelated donor. Thosewho received allo-HCT from an HLA-mismatched or haplo-
identical donor were excluded. No patient received an ex-vivo T-
cell depleted graft. Patients with chronic myelo-monocytic
leukemia were also excluded.
To avoid the competing risk of early death, patients who died
before day 100 were excluded from the derivation (n = 68, 14.8%)
and validation (n = 60, 13.3%) cohorts.
STATISTICAL ANALYSIS
Patients and donor characteristics, transplantation modalities
and early complications that occurred within 100 days post-
transplant were taken into account. Inclusion of a variable in the
predictive model was based on clinical relevance. The following
variables were chosen: age at time of transplant; IPSS and
cytogenetic score [10,11]; disease status at transplant (responder
vs. non responder) according to IWG 2006 criteria [12]; bone
marrow blast count at transplant (<5% vs.  5%), HLA matching
(sibling vs. HLA-matched unrelated donor); sex mismatch defined
as male patient receiving graft from a female; CMV positive status
for donor and recipient; use of anti-thymocyte globulin (ATG);
source of stem cells (bone marrow vs. PBSC); intensity of the
conditioning regimen as defined by Bacigalupo et al [13]; grade of
acute GVHD (0/I, II, III/IV) within 100 days post-transplant
according to standard criteria [14]; early relapse before day 100
post-transplant; lack of platelet recovery [15]. The latter was
defined by occurrence of transfusion-independent platelet count
20 G/L for the 7 consecutive days leading up to day 100 post-
transplant even if platelet count may have then decreased at some
point.
Quantitative variables are expressed as means (standard
deviation) if the distribution was normal and as medians
(interquartile range) if the distribution is otherwise. Categorical
variables are expressed as frequencies and percentages. Normality
of distribution was checked graphically and with use of the
Shapiro–Wilk test. Using the Kaplan-Meier method, we estimated
OS from 100 days after transplant, the landmark time point.
Before developing the multivariable prognostic model with
Cox’s proportional hazard regression model, the log-linearity
assumption for age was assessed using Martingale residual plots
and the restricted cubic spline functions [16]. Since no evidence of
a non-log-linear relationship was shown, age was introduced as a
linear term in the multivariable model. The proportional hazards
assumption was assessed for each candidate predictor by plotting
the Schoenfeld residuals against the rank of survival time [17].
Irrespective of their univariate association with OS, all variables
were entered into the multivariable prognostic regression model.
Missing data for individual variables ranged from 0 to 9.9% (1.7% of
missing data points) leading to 86.0% of patients with no data
missing data (ie. complete data) in the multivariable prognostic
regression model. To prevent case deletion in multivariable
analysis, missing data were imputed by simple imputation using
a regression-switching approach (chained equations using all
variables; death status and survival times introduced after
logarithmic transformation) with predictive mean-matching
method for the following: continuous variables; logistic regression
model for binary variables; ordinal logistic regression for ordered
categorical variables [18].
After a backward selection procedure, variables with low
prognostic value (P > 0.05) were not kept in the final Cox model.
10 A. Caulier et al. / Current Research in Translational Medicine 67 (2019) 8–15The results of significant predictors were reported as hazard ratios
(HRs) and 95% confidence intervals (CI). The proportional hazard
assumption was also assessed by plotting the Schoenfeld residuals
for the prognostic index derived from the selected model againstTable 1
Patient and disease characteristics at transplant and early post-transplant complication
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Lack of platelet recovery before day 100a, n(%)
No
Yes
Relapse before day 100a, n(%)
No
Yes
Abbreviations: RA, refractory anemia; RARS, RA with ring siderobalsts; RCMD, Refractory 
in transformation <30% of marrow blasts; HLA, human leukocyte antigen; CMV, cytomeg
body irradiation; GVHD, graft-versus-host disease; d100, day 100.
a Indicates selected variables for entrance into the multivariable prognostic regressio
b Defined as male patient receiving graft from a female.the rank of survival time. The performance of this model was
assessed through its calibration and discrimination. In particular,
calibration (i.e. the predicted-to-observed survival agreement) was

























































































cytopenia with multilineage dysplasia; RAEB, RA with excess of blasts; RAEB-t, REAB
alovirus; PBSC, peripheral blood stem cells; ATG, anti-thymocyte globulin; TBI, total
n model.
Fig. 1. Calibration of survival probabilities. The continuous prognostic model in the
derivation cohort highlighted low (0 points), intermediate (1-3 points) and high (>
3 points) risk score according to corresponding survival probability. Origin of the
landmark analysis is day 100.
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were determined by the prognostic index’s distribution.
Discrimination was assessed via the Harrell’s c-index of
agreement [16], which indicates to what extent the model
distinguishes between patients who will die from those who will
survive. This c-statistic is expected to range from 0.60 to 0.85 for
survival data [19]. The predicted overall survival probabilities were
derived from the baseline survival estimates at the mean values of
selected variables. To account for the reported overestimation of
regression coefficients in prognosis models derived from multivari-
able regression analysis [16], we performed an internal validation by
using bootstrap resampling with 200 repetitions to estimate the
shrinkage factor and the c-statistic corrected for over-optimism.
For clinical purposes, a point-scoring model (e.g. a risk
assessment tool) was created by assigning one point to the lowest
hazard ratio (the constant factor that reflect 1 point in final point
system) and by weighing every other one to the nearest
approximation of the ratio of its HR with constant factor. The
predictive accuracy of the point-scoring model was assessed by the
previously mentioned method.
For the external validation, calibration and discrimination
performances were assessed for continuous and discreet point-
score models in the validation dataset. The predicted survival
probabilities calculated within the validation dataset came from
the coefficient estimates (after applying the shrinkage factor) and
the baseline survival estimate from the derivation dataset.
Statistical testing was done at the two-tailed α level of 0.05.
Data were analyzed using the SAS software package, release 9.4
(SAS Institute, Cary, NC).
RESULTS
Database
The derivation cohort included 393 patients and the validation
cohort included 391 patients. The median follow-up from
transplantation respectively for the derivation and validation
cohort was 3.8 years (range, 0.3 to 11.8 years) and 2.9 years (range,
0.4 to 5.5 years). Table 1 reports baseline characteristics and early
post-transplant complications of both cohorts. Mean recipient age
was 52.0  10.8 years in derivation cohort, and 56.6  9.9 years in
validation cohort. In the derivation and validation cohort,
respectively 37.9% and 41.2% of recipients were female. Main
differences were higher incidence of intermediate2/high IPSS
score, broader use of ATG, increased pre-transplant treatment
using hypomethylating agents, and less-intensive conditioning in
the validation cohort. In the derivation cohort,173 deaths occurred,
and 145 deaths occurred in the validation cohort. Mean 3-year OS
was 56% for the derivation cohort and 63% for the validation cohort.
Prognostic Scoring Model
Univariate associations of clinically relevant predictors with 3-
year OS in the derivation cohort are available in Supplementary
Table S1.
After a stepwise-backward selection procedure, the only
independent risk factors of 3-year OS were the following:
1 Grade of acute GVHD (HR for grade II: 1.7; 95%CI: 1.2 - 2.5; HR for
III/IV: 2.6; 95%CI: 1.8 to 3.8 using 0/I as reference).
2 Lack of platelet recovery before day 100 (HR: 3.6; 95%CI, 2.2 -
5.8).
3 Relapse before day 100 (HR: 6.7; 95%CI: 4.5 - 10.0).
See Table 1 for observed occurrence of these three complica-
tions among patients in both cohorts.Internal validation
There was no deviation from proportional hazard assumptions
for the prognostic index derived from the selected model. After
correction for over optimism, the discrimination of the prognostic
scoring model was 0.67 (95%CI: 0.63-0.71) with a shrinkage factor
of 0.903. Calibration at 1 to 3 years from transplantation was good
in all groups, implying that the predicted survival for each group
were close to the observed ones (Fig. 1, Table 3, and Supplementary
Table S2). Formulae and coefficients to estimate 1 to 3-year
survival probability are detailed in the appendix.
External Validation
The discrimination value in the validation dataset was 0.65 (95%
CI: 0.61-0.69). After the shrinkage of the coefficients, the
calibration stayed satisfactory despite a slight underestimation
observed in the highest risk group: 21.9 vs 9.7 for 3-year OS (see
Supplementary Table S2).
Post-Transplant Scoring System (PTSS)
As shown in Table 2, grade of acute GVHD, lack of platelet
recovery and relapse within 100 days after transplant were
respectively assigned 1, 2 and 4 points. The point score model
ranged from 0 - 8, discriminating low (0), intermediate (1 - 3),
and high-risk (4 - 8) patients, according to survival prognosis.
The observed 3-year OS after transplantation in patients with
low, intermediate and high scores was accordingly 70% (95%CI:
63 - 76%), 46% (95%CI, 38 - 55%) and 6% (95%CI, 2 - 16%). In both
datasets, discrimination  and calibration were satisfactory
(Table 3).
How to Use the PTSS: Proposal of an Algorithm
Patients requiring intense care due to early post-transplant
complications are almost systematically transferred [15]. However,
Table 2
Scoring system of mortality risk according to early post-transplant complications.
Predictors Points
0 1 2 4
Grade of acute GVHD
Lack of platelet recovery before day 100




















GVHD = graft-versus-host disease.
a Score: addition points of the 3 predictors described above.
Fig. 2. Proposal of an algorithm for patients requiring transfer to ICU after day 100
post-transplant. (* examples of ICU scoring systems20,24,25).
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100 post-transplant is more difficult to make.
As shown in Fig. 2, the PTSS together with other scoring systems
such as the Sepsis-Related Organ Failure Assessment (SOFA) [20]
can facilitate the decision-making process before transferring a
patient to the ICU. According to the expected 3-year survival
observed with the PTSS, patients with a low score should be
transferred regardless of their current complications, and those
with a high score are less likely to benefit from intensive care. Prior
to making a final decision regarding specific ICU care, patients with
an intermediate PTSS score must undergo additional screening
based on standard ICU scores [20–23]. Therefore, they can be
transferred to the ICU if their SOFA score, for instance, is A, B or C
(less than 10 points).
DISCUSSION
To our knowledge, this is the first study to propose a clinical tool
generated from variables evaluated after allo-HCT. This tool allows
for early post-transplant prognostic assessment in patients with
MDS.
Several approaches have been used to attempt to predict
patient outcome after allo-HCT. One of these scoring approaches is
to apply well-established disease-specific prognostic scores at the
time of transplant [1,5,6], which poses significant limitations. By
definition, patients eligible for allo-HCT are usually classified as
“high-risk” per the given scoring system. While these scores areTable 3





Low (0) 37/207 0.820 0
Intermediate (1 to 3) 38/142 0.727 0
High (4 to 8) 37/44 0.159 0
2-year survival
Risk group
Low (0) 52/207 0.744 0
Intermediate (1 to 3) 63/142 0.544 0
High (4 to 8) 39/44 0.109 0
3-year survival
Risk group
Low (0) 60/207 0.697 0
Intermediate (1 to 3) 72/142 0.463 0
High (4 to 8) 41/44 0.055 0
C-statistic (95%CI) 0.67 (0.63-0.71)a
Observed values were calculated using Kaplan–Meier estimates.
In the derivation data set, predicted estimates in each risk group were calculated as the m
predictor). In the validation dataset, predicted estimates use shrinkage factor based on 
information).
a C-statistic corrected for over-optimism.helpful for decision-making in terms of transplant, they overlook
key transplant-related variables [6,7].
The main body of literature investigating prognostic factors
assessed after hematopoietic cell transplant was published by
the intensivist community. While of interest for patients
admitted to the ICU, such studies fail to include key prognos-
ticators such as disease characteristics and transplantation
modalities [20,24–26]. For MDS in particular, other authors have
combined disease-specific scores (R-IPSS) with other variables
assessed at the time of transplant (HCT-CI) to assess prognosis
after allo-HCT [5].
In this study, we computed a comprehensive set of data into a
multivariable Cox model encompassing patient characteristics as
well as detailed transplantation modalities. In contrast with
previously reported models [7–11], we also included crucial early
post-transplant complications using a landmark analysis at day
100. Notably, we considered IPSS score rather than IPSS-Revised
score for baseline disease characteristics, as recommended by the
European LeukemiaNet [27]. In addition, IPSS-R do not seem toValidation cohort
redicted Death/N Observed Predicted
.832 31/244 0.871 0.812
.686 36/109 0.669 0.655
.202 23/38 0.395 0.250
.745 61/244 0.738 0.715
.550 45/109 0.576 0.510
.087 27/38 0.283 0.114
.692 68/244 0.697 0.658
.475 48/109 0.537 0.434
.050 29/38 0.219 0.069
0.65 (0.61-0.69)
ean predicted probabilities by the Cox regression model (using score as continuous
bootstrap validation in the derivation data set (see method and appendix for more
A. Caulier et al. / Current Research in Translational Medicine 67 (2019) 8–15 13change the outcome after allo-HCT compared to IPSS [28].
Interestingly, these post-transplant complications were found to
be the only independent risk factors associated with decreased 3-
year OS, whereas pre-transplant parameters were not found to be
independent risk factors. Although pre-transplant factors such as
disease characteristics and transplantation modalities play a major
role in post-transplant survival, early post-transplant complica-
tions appeared to override the prognostic impact of pre-transplant
parameters.
Strikingly, lack of platelet recovery at day 100 was a strong and
independent predictor of low OS. The prognostic impact of
impaired platelet recovery has already been described by others
[29,30], but these studies observed heterogeneous cohorts in
terms of disease type and transplant modalities. Therefore, this is
the first clear report of the negative and independent impact of
poor platelet recovery on long-term survival. Only a few patients
who did not recover their platelet count before day 100 showed
early relapse: 6/25 in derivation cohort; 4/25 in validation cohort.
Regarding this, absence of durable platelet recovery could also
reflect poor graft function, when not reflecting viral/bacterial
infections or linked to GVHD [4,31,32]. Predictably, relapse before
day 100 along with grade 2-4 acute GVHD adversely impacted
survival in our model [33].
In light of the rising number of patients undergoing allo-HCT,
the decision-making process of whether a patient should be
treated with curative or palliative intent ought to be guided by
robust statistical models. Despite the recent changes in allo-HCT
management, expected and observed rates overlapped with our
prognostic model when applied to a more recent cohort of
patients (ie. validation cohort). In fact, older patients could still
benefit from allo-HCT, with more severe disease highlighted by a
higher-risk IPSS score. The recent growing use of PBSC as a
transplant source and, therefore, the prophylactic use of ATG for
GVHD [34] partly explain these differences. Interestingly, we
observed that more patients received a myeloablative condition-
ing (MAC) regimen in the validation cohort, despite of increased
age of transplantation.
For daily use, the PTSS, a clinical risk assessment tool was
elaborated, stratifying patients with a score according to the
following levels of mortality risk: low (0), moderate (1-3) and
high (4).
The PTSS score takes into account scores relative to the
following variables: acute GVHD grade; lack of platelet recovery
before day 100; relapse before day 100. This proposed clinical
scoring tool could provide for a more cost-effective use of medical
resources because it aims to more appropriately select those
patients who will truly benefit from curative care, including
intensive care.
Dramatically, early relapse systematically drives patient to the
high-risk group as opposed to the occurrence of acute GvHD, which
more weakly affects prognosis. Nevertheless, a prospective
evaluation is needed to prove the cost-effectiveness of such a
strategy.
According to recommendations from the SFGM-TC, patients
requiring intensive care during the early post-transplant period
should be transferred to the ICU regardless of their complication
severity [15].
The PTSS can be helpful in making the decision to proceed to
intensive care for patients surviving more than 100 days after allo-
HCT. Indeed, it seems difficult to refuse to transfer a patient with a
low PTSS-score (estimated 3-year OS of 70%). In contrast, with 6%
of estimated 3-year OS, patients with a high score are less likely to
benefit from ICU admission. Screening systems based on standard
ICU scores20,24,25 would be more helpful when it comes to patients
with intermediate PTSS-score (estimated 3-year OS of 46%).
Nevertheless, such hypothesis should be further validated in anindependent prospective cohort of patients requiring treatment in
intensive care settings.
One of the strengths of this study was the clear-cut definition of
the predictor variables, which relevance are in line with previous
studies. An additional strength is the simplicity of use of our
prognostic assessment tool, suitable for clinical practice and
bridging the gap between scores typically used by onco-
hematologists and those applied in the ICU.
Due to prospective data collection in the ProMISe database,
some variables were not included in the model, such as
comorbidity evaluation, development of infection, acute kidney
injury, or sinusoidal occlusion syndrome. However, occurrence of
such complications and severe comorbidities were considered
beforehand with regards to conditioning intensity, which was
included in our multivariable model.
Finally, we would like to mention that an increasing amount of
attention is being focused on molecular data in MDS. Due to the
inclusion years, such data were not available in our database. If
molecular data are suggested to improve the risk stratification of
MDS patients [35], such an approach has yet to be prospectively
validated in hematopoietic transplantation procedures. Given our
aim to develop a simple and usable clinical score, adding such
specific data did not appear relevant to us. Extending our
prognostic score to patients who underwent allo-HCT for other
hematological disorders, malignant or not, or other types of
transplant is an encouraging potential next step that will ideally
require prospective validation in homogenous cohorts.
CONCLUSION
In this study, we created and validated the first prognostic score
based on early post-transplant complications to quickly and simply
estimate the survival probability of myelodysplastic patients who
survived more than 100 days after allo-HCT. Our findings support
the robustness, the reliability and the reproducibility of this
scoring system. The potential extension of our scoring system, to
patients with other hematologic malignancies will be the next
phase for the PTSS we propose. This next step will require further
prospective evaluation.
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using the continuous prognostic model
Step 1: Calculate S
S = [-1.2706 * (Platelet recovery) + 0.5251 * (acute GVHD II) +
0.9592 * (acute GVHD III/IV) + 1.9011 * (Relapse)] * 0.9027
Where
(1) Platelet recovery =
a 0.0636 if the patient recovers their platelet count before day
100
b 0.9364 if the patient doesn’t recover their platelet count
before day 100
(2) Acute GVHD II =
a 0.7659 if the patient has grade II acute GVHD
b 0.2341 if the patient does not have grade II acute GVHD
(3) Acute GVHD III/IV =
a 0.8524 if the patient has grade I/IV acute GVHD
b 0.1476 if the patient does not have grade I/IV acute GVHD
(4) Relapse =
a 0.9109 if the patient relapses before day 100
b 0.0891 if the patient doesn’t relapse before day 100
(5) 1.2706, 0.5251, 0.9592 and 1.9011 = regression coefficients
estimated for the derivation dataset
(6) 0.9027 = the shrinkage factor estimated using bootstrap
validation for the derivation dataset
Step 2: Calculate survival probability using S
1-year survival probability = 100 * 0.7374exp(S)
2-year survival probability = 100 * 0.6130exp(S)
3-year survival probability = 100 * 0.5426exp(S)
Where 0.7374, 0.6130 and 0.5426 are the survival rate at the
mean values of predictors in derivation dataset.
Example: a patient who recovers platelet count, relapses before
100 days and has grade 0 acute GVHD.
Step 1: Calculate S = [1.2706 * (0.0636) + 0.5251 * (0.2341) +
0.9592 * (0.1476) + 1.9011 * (0.9109)] * 0.9027 = 1.2515
Step 2: Calculate survival probability using S
1-year survival probability = 100 * 0.7374exp(1.2515) = 34.5%
2-year survival probability = 100 * 0.6130exp(1.2515) = 18.1%
3-year survival probability = 100 * 0.5426exp(1.2515) = 11.8%
Appendix B. Supplementary data
Supplementary material related to this article can be found, in
the online version, at doi:https://doi.org/10.1016/j.
retram.2018.08.003.
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